Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Neoplasms 2 Esophageal Neoplasms 2 Breast Neoplasms 2 Lung Neoplasms 1 Gastrointestinal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Cancer Metastatic 1

Interventions

pembrolizumab 37 Carboplatin 26 Radiotherapy 23 Cisplatin 19 Paclitaxel 18 Erlotinib Hydrochloride 18 Docetaxel 15 Gemcitabine 14 Pemetrexed 13 Etoposide 12 osimertinib 11 Nivolumab 11 durvalumab 9 atezolizumab 9 Radiosurgery 8 Magnetic Resonance Spectroscopy 8 Cetuximab 7 Specimen Handling 6 Cyclophosphamide 6 130-nm albumin-bound paclitaxel 6 Taxes 5 Immunoglobulin G 5 Gefitinib 5 Biopsy 5 Bevacizumab 5 fludarabine 4 Radiation 4 Ipilimumab 4 Disulfides 4 Albumin-Bound Paclitaxel 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Lung Neoplasms × patritumab deruxtecan × Clear all

NCT07286149 2026-05-26

MK-3475-01F

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡